Molecular Partners AG

Molecular Partners AG (MOLN) Stock Analysis

$3.215

-0.032 (-0.98%)At close

Loading chart…
High
3.595
Open
3.380
VWAP
3.34
Volume
4.79K
Mkt Cap
233.98M
Low
3.215
Amount
16.01K
EV/EBITDA, TTM
0.00

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

AI analysis of Molecular Partners AG (MOLN)

Hold

Molecular Partners AG (MOLN) is currently trading at $3.48, significantly below its 52-week high of $5.36, indicating potential upside. However, the stock has a low RSI of 35.332, suggesting it is oversold, but it has also shown a 5-day decline of 3.06%. The forward P/E ratio is 1.7027, indicating potential for growth, but the company is currently facing substantial losses with a net income of -13,144,000 CHF in Q1 2026. The main risk is its negative earnings trend, with EPS expected at -0.46 for the last quarter, which could further pressure the stock price.

Valuation Metrics

The current forward P/E ratio for Molecular Partners AG (MOLN) is 1.70, compared to its 5-year average forward P/E of -1.00.

Forward P/E

Fair
5Y Average P/E
-1.00
Current P/E
1.70
Overvalued
2.47
Undervalued
-4.47

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
0.88
Current EV/EBITDA
0.00
Overvalued
2.42
Undervalued
-0.66

Forward P/S

Fair
5Y Average P/S
22.98
Current P/S
3.04
Overvalued
64.31
Undervalued
-18.35

Alphio AI Price Scenarios for MOLN

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%MOLN

$3.68

Scenario price

B

Base

Base · 50%MOLN

$3.21

Scenario price

B

Bear

Bear · 25%MOLN

$3.07

Scenario price

Whales holding MOLN

B

BVF Partners L.P.

+ HoldingMOLN

+8.72%

3M Return

S

Suvretta Capital Management, LLC

+ HoldingMOLN

+0.00%

3M Return

Events Timeline

2026-10-22 (ET)

06:00:00

Molecular Partners Selects MP0730 as Lead Candidate

2026-07-02 (ET)

05:30:00

Molecular Partners and Orano Med Begin MP0712 Clinical Trial

2026-05-31 (ET)

16:30:00

Molecular Partners to Present MP0712 Trial Progress at 2026 ASCO Meeting

2026-05-01 (ET)

07:10:00

Molecular Partners Publishes MP0317 Clinical Data

2026-04-19 (ET)

13:00:00

Molecular Partners Presents New Data on MP0632 at AACR Meeting

News

MOLN FAQ — answered by Alphio AI

Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. It operates in the Healthcare sector.

Molecular Partners AG (MOLN) is currently trading at $3.48, significantly below its 52-week high of $5.36, indicating potential upside. However, the stock has a low RSI of 35.332, suggesting it is oversold, but it has also shown a 5-day decline of 3.06%. The forward P/E ratio is 1.7027, indicating potential for growth, but the company is currently facing substantial losses with a net income of -13,144,000 CHF in Q1 2026. The main risk is its negative earnings trend, with EPS expected at -0.46 for the last quarter, which could further pressure the stock price.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading